losartan + hidroclorotiazida aurovitas 50 mg + 12.5 mg comprimido revestido por película
generis farmacêutica, s.a. - losartan + hidroclorotiazida - comprimido revestido por película - 50 mg + 12.5 mg - losartan de potássio 50 mg ; hidroclorotiazida 12.5 mg - losartan and diuretics - genérico - duração do tratamento: longa duração
losartan + hidroclorotiazida aurovitas 50 mg + 12.5 mg comprimido revestido por película
generis farmacêutica, s.a. - losartan + hidroclorotiazida - comprimido revestido por película - 50 mg + 12.5 mg - losartan de potássio 50 mg ; hidroclorotiazida 12.5 mg - losartan and diuretics - genérico - duração do tratamento: longa duração
fosaprepitant hikma 150 mg pó para solução para perfusão
hikma farmacêutica (portugal), s.a. - fosaprepitant - pó para solução para perfusão - 150 mg - fosaprepitant dimeglumina 245.3 mg - aprepitant - genérico - duração do tratamento: longa duração
losartan + hidroclorotiazida aurovitas 100 mg + 12.5 mg comprimido revestido por película
generis farmacêutica, s.a. - losartan + hidroclorotiazida - comprimido revestido por película - 100 mg + 12.5 mg - hidroclorotiazida 12.5 mg ; losartan de potássio 100 mg - losartan and diuretics - genérico - duração do tratamento: longa duração
fosaprepitant accord 150 mg pó para solução para perfusão
accord healthcare, s.l.u. - fosaprepitant - pó para solução para perfusão - 150 mg - fosaprepitant dimeglumina 245.3 mg - aprepitant - genérico - duração do tratamento: longa duração
losartan + hidroclorotiazida aurovitas 100 mg + 25 mg comprimido revestido por película
generis farmacêutica, s.a. - losartan + hidroclorotiazida - comprimido revestido por película - 100 mg + 25 mg - hidroclorotiazida 25 mg ; losartan de potássio 100 mg - losartan and diuretics - genérico - duração do tratamento: longa duração
teriparatide sun
sun pharmaceutical industries europe b.v. - teriparatida - osteoporosis; osteoporosis, postmenopausal - homeostase de cálcio - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
kauliv
strides pharma (cyprus) limited - teriparatida - osteoporosis; osteoporosis, postmenopausal - homeostase de cálcio - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agentes antineoplásicos - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
evotaz
bristol-myers squibb pharma eeig - cobicistat, atazanavir - infecções por hiv - antivirais para uso sistêmico - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 e 5.